Alcon Inc. (ALC)
$
74.08
+1.48 (2.00%)
Key metrics
Financial statements
Free cash flow per share
3.2276
Market cap
35.9 Billion
Price to sales ratio
3.5804
Debt to equity
0.2375
Current ratio
2.6015
Income quality
1.9155
Average inventory
2.4 Billion
ROE
0.0493
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The financial data pertains to the fiscal year 2024. During this period, the company incurred an income tax expense of $238,000,000.00 indicating its tax obligations. The net total of other income and expenses is -$157,000,000.00 reflecting non-core financial activities. Furthermore, the gross profit ratio is 0.56 reflecting the efficiency of the company's production and sales operations. The net income ratio is 0.10 reflecting the company's profitability margin. Alcon Inc. is dedicated to advancing eye care through its Surgical and Vision Care segments, offering a comprehensive range of products such as intraocular lenses, surgical equipment, diagnostic tools, contact lenses, and ocular health solutions. Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is committed to innovation and quality, ensuring that healthcare professionals and patients benefit from its advanced technologies and eye care solutions. The stock is reasonably priced at $77.25 appealing to a broad range of investors. With a mid-range market capitalization of $36,625,152,000.00 the company is a steady performer. Additionally, the stock has an average trading volume of 2,125,182.00 indicating moderate liquidity. Alcon Inc. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company’s strategic focus on enhancing vision care and developing advanced surgical solutions positions it as a vital contributor in the eye care market, meeting the diverse needs of eye care professionals and patients worldwide.
Investing in Alcon Inc. (ALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Alcon Inc. stock to fluctuate between $71.55 (low) and $99.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-10-15, Alcon Inc.'s market cap is $36,625,152,000, based on 494,400,000 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Alcon Inc. has a Lower Market-Cap, indicating a difference in performance.
Alcon Inc. pays dividends. The current dividend yield is 0.36%, with a payout of $0.33 per share.
To buy Alcon Inc. (ALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALC. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Revenue: $9,911,000,000 | EPS: $2.06 | Growth: 4.04%.
Visit https://www.alcon.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $101.10 (2024-09-12) | All-time low: $55.21 (2022-10-13).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC (“Glass Lewis”) related to STAAR's pending merger with Alcon (SIX/NYSE: ALC): The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis.
prnewswire.com
CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement outlining its opposition of the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC): We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company.
businesswire.com
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR's merger with Alcon (SIX/NYSE: ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders. Stephen Farrell, CEO of STAAR, said, “Prior to the Alcon.
globenewswire.com
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).
businesswire.com
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced,.
seekingalpha.com
Alcon Inc. gets upgraded to a Buy again after my prior hold rating. Upside could come from macro-level clinical demand in the eyecare niche, but also a diverse and growing product portfolio in both the consumer and surgical space. Operating cashflow growth is proven, although there is limited dividend growth history as the firm only went public in 2019 after its spinoff from Novartis.
businesswire.com
ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma” or “the Company”) (TSX:ALC), today took delivery of the Algoma Legacy, the first of three new methanol-ready Kamsarmax-sized ocean belt self-unloading vessels. With this addition, the Company will have an ownership interest in 100 vessels across its global fleet, a historic milestone that underscores its leadership in long-term growth in diversified short sea shipping markets. “This is a proud moment on two fronts: t.
businesswire.com
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposition to the Company's proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. Yunqi Capital released the following open letter to fellow STAAR shareholders explaining why it opposes the transaction: September 22, 2025.
zacks.com
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.
zacks.com
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
See all news